Clinical Study

R1216- Randomized Phase II/III Trial Of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, Or Cisplatin-Atezolizumab In Pathologic High-Risk Squamous Cell Cancer Of The Head And Neck

Posted Date: Jan 18, 2021

  • Investigator: Sara Medek
  • Specialties: Cancer, Head and Neck Cancer, Oncology, Radiation Oncology
  • Type of Study: Drug

The main purpose of this study is to determine if the combination of docetaxel-cetuximab and IMRT is superior in terms of overall survival (OS) compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, HPV-negative HNSCC.


To Be Eligible: Must Have Diagnosis Of Stage Iii Or Iv Head And Neck Squamous Cell Carcinoma (Hnscc) Involving The Oral Cavity (Excluding Lips), Oropharynx (P16 Negative), Larynx, Or Hypopharynx, Undergone Gross Total Surgical Resection Within 63 Days, Zubrod Performance Status Of 0-1, Adequate Organ Function, No Prior Malignancy Within 3 Years, No Prior Cancer Therapy For Study Cancer, No Previous History Of Organ Transplant Or Immunodeficiency, No Autoimmune Disease


Hnscc, Head And Neck Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.